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Abstract: Zika virus (ZIKV), a mosquito-transmitted flavivirus, emerged in the last decade causing
serious human diseases, including congenital microcephaly in newborns and Guillain-Barré syndrome
in adults. Although many vaccine platforms are at various stages of development, no licensed
vaccines are currently available. Previously, we described a mutant MR766 ZIKV (m2MR) bearing an
E protein mutation (N154A) that prevented its glycosylation, resulting in attenuation and defective
neuroinvasion. To further attenuate m2MR for its potential use as a live viral vaccine, we incorporated
additional mutations into m2MR by substituting the asparagine residues in the glycosylation sites
(N130 and N207) of NS1 with alanine residues. Examination of pathogenic properties revealed that
the virus (m5MR) carrying mutations in E (N154A) and NS1 (N130A and N207A) was fully attenuated
with no disease signs in infected mice, inducing high levels of humoral and cell-mediated immune
responses, and protecting mice from subsequent lethal virus challenge. Furthermore, passive transfer
of sera from m5MR-infected mice into naïve animals resulted in complete protection from lethal
challenge. The immune sera from m5MR-infected animals neutralized both African and Asian lineage
viruses equally well, suggesting that m5MR virus could be developed as a potentially broad live virus
vaccine candidate.
Keywords: Zika virus; NS1 protein; glycosylation; attenuation; vaccine candidate

1. Introduction
Zika virus (ZIKV) belongs to the family Flaviviridae and genus Flavivirus. It is primarily transmitted
by Aedes species of mosquito, but vertical and sexual transmissions have also been reported [1–3].
Historically, the majority of ZIKV infections in humans were asymptomatic, but in about 20% of
cases, were associated with mild flu-like illnesses with disease symptoms, such as fever, conjunctivitis,
rash, and joint pain, which may last less than a week [2]. However, the virus remerged in the last
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decade in the Americas, the Caribbean, and the Pacific regions [4], causing severe diseases. Since
its introduction into the Americas in 2014, over one million individuals are suspected to have been
infected with ZIKV [5]. So far, 27 countries and territories in the Americas have reported the association
between the ZIKV infections and Congenital Zika Syndrome, Guillain-Barré syndrome (GBS), and other
neurological disorders [6–8].
ZIKV is enveloped and consists of approximately 11 kb positive-sense, single-stranded RNA
genome. The viral genome has a 50 cap and 50 - and 30 -UTRs and contains a single open reading frame
(ORF), which is translated as a single polyprotein at the endoplasmic reticulum (ER) membrane [9,10].
The polyprotein is cleaved and processed by viral and host proteases to generate three amino-terminal
structural proteins (capsid, C; pre-membrane, prM; envelope, E) and seven carboxyl-terminal
non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [10]. The structural
proteins are involved in virion structure, assembly, attachment, and entry into host cells [11]. The NS
proteins are associated with the ER and participate in essential functions, such as genome replication,
virion assembly, polyprotein processing, and evasion of host antiviral responses [12–14]. Importantly,
it appears that the flavivirus E protein elicits neutralizing antibody responses [15–17], while the NS1
protein induces non-neutralizing antibodies [18]. However, these NS1 antibodies have been shown to
mediate constant region (Fc)-dependent cell-mediated immunity against ZIKV [4,19–23].
In dengue virus (DENV) and other flavivirus infected cells, NS1 is synthesized as a soluble
monomer, which rapidly dimerizes in the lumen of ER [24–26]. NS1 exists as various oligomeric
forms in different cellular locations [27–29]. Dimeric NS1 is localized in the lumen of the ER, secretory
vesicles, or on the cell surface (membrane-bound NS1, mNS1) [29]. Intracellular NS1 plays an
essential role in virus replication as a cofactor and has been shown to co-localize with dsRNA
intermediate in replication complexes [30,31]. A proportion of NS1 dimers form hexamers in the
Golgi that are transported to the cell surface and secreted (secreted NS1, sNS1) [32]. NS1 also contains
epitopes for protective antibodies [4,33]. NS1 is a multifunctional, highly immunogenic protein and
plays a role in pathogenesis and immune evasive functions [34,35]. However, the role of NS1 in
immunopathogenesis and the potential of NS1-mediated immune responses in protection against
ZIKV remain incompletely understood.
Sequence analysis and experimental studies have revealed that structural and non-structural
proteins of flaviviruses contain several N-linked glycosylation sites [32,36–38]. Particularly, it has
been shown that the glycosylation sites in E and NS1 proteins are conserved among members of
the flavivirus genus [39–42]. In majority of isolated ZIKV strains, the E protein is glycosylated at
asparagine 154 (N154) located in the domain I (DI) [43], whereas there are two glycosylation sites
present in NS1 protein: one at N130 located in the wing domain and the other at N207 located in the
continuous β-ladder domain [44]. Although, most flavivirus NS1 contain N-linked glycosylation sites
at N130 and N207, in West Nile virus (WNV), an additional glycosylation site is present at position
N175, while the second glycosylation site in yellow fever virus (YFV) is located at N208 [36,40–42].
The function of NS1 glycosylation has been studied for other flaviviruses. Mutation of the N207
site in DENV-2 led to reduced virus growth in cell culture and decreased neurovirulence in mice [45].
On the other hand, mutation at N130 of chimeric tick-borne encephalitis (TBE)/DEN-4 virus [containing
membrane and envelope (ME ) structural genes of TBE virus (TBEV) and remaining genes from
(DENV-4)] resulted in reduced virus titers in cell culture and decreased mouse neurovirulence as
opposed to increased neurovirulence in an N207 mutant [46,47]. In YFV, ablation of the N130 site alone
or in combination with N207 resulted in reduced virus yields, cytopathic effect, NS1 secretion, plaque
size, and neurovirulence [48]. In WNV, ablation of NS1 glycosylation sites resulted in attenuation
of neuroinvasive properties of the virus, while the removal of glycosylation sites in both E and NS1
proteins completely attenuated virus neuroinvasiveness and neurovirulence in a mouse model [42].
Overall, these studies suggest that NS1 glycosylation appears to play a vital role in viral replication
and pathogenesis.
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We previously generated E glycosylation mutant ZIKVs, in which four amino acids spanning the
glycosylation site were deleted (m1MR) or N154 was changed to A154 (m2MR) and showed that the
mutant viruses were significantly attenuated in pathogenicity and defective in neuroinvasion [49].
In the genomic background of the m2MR mutant virus, we explored whether additional incorporation
of mutations in the NS1 glycosylation sites would further attenuate the resulting virus to be used as a
potential live virus vaccine candidate. Our data presented here showed that the mutant ZIKV that
encoded non-glycosylated E and NS1 proteins was highly attenuated in pathogenicity and conferred
complete protection of animals upon lethal challenge with ZIKV.
2. Materials and Methods
2.1. Ethics Statement
This study was performed per the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The protocol (# 1323) was approved by the
Institutional Animal Care and Use Committee (IACUC) at the University of Nebraska-Lincoln (UNL).
All animals were housed in the Life Sciences Annex building at the university. All procedures were
conducted under anesthesia with isoflurane, and all efforts were made to minimize animal suffering.
2.2. Cells and Viruses
Vero, the African green monkey kidney cells (Cercopithecus aethiops, CCL-81) and C6/36 mosquito
cells (Aedes albopictus, CRL-1660) were obtained from ATCC (Manassas, VA, USA). Vero cells were
grown and maintained in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen, Carlsbad, CA, USA)
supplemented with 10% fetal bovine serum (heat-inactivated) (FBS; HyClone Laboratories, Logan, UT,
USA), 1% penicillin/streptomycin (PS) (Invitrogen, Carlsbad, CA, USA) in humidified chamber with 5%
CO2 at 37 ◦ C, whereas C6/36 cells were maintained similarly at 32 ◦ C. African lineage parental ZIKV
strain MR766 and the infectious clone derived recombinant MR766 (rMR) virus have been described
previously [49]. American/Asian lineage PRVABC59 ZIKV virus was obtained from Barbara Johnson
at the Centers for Disease Control and Prevention, Fort Collins, CO, USA. American/Asian lineage
MEX1–7 strain of ZIKV was obtained from S. Byrareddy (University of Nebraska Medical College).
Virus stocks were prepared by infecting a confluent monolayer of Vero cells at multiplicity of infection
(MOI) of 0.1 plaque-forming unit (PFU) per cell and incubating in virus growth medium (VGM)
(DMEM containing 2% FBS, 20 mM hydroxyethyl piperazine ethane sulfonic acid (HEPES), 1 mM
sodium pyruvate, non-essential amino acids, and 1% PS) for four days, as described previously [49,50].
Multistep growth analysis was conducted using the MOI of 0.1 PFU/cell. Following adsorption of the
virus, the inoculum was removed, cells were washed twice in phosphate-buffered saline (PBS), VGM
was added, and the cells were incubated at 37 ◦ C/5% CO2 incubator. Small aliquots of infected cell
culture supernatants (CCS) at various days post-infection (dpi) were collected, clarified, and stored
at −80 ◦ C before virus titration. For glycan analysis of NS1 protein, cells were infected at an MOI of
1 PFU/cell, and CCSs were collected at 2 dpi for further analysis.
2.3. Reagents and Antibodies
Restriction enzymes, DNA modifying enzymes, ProtoScript II First Strand cDNA Synthesis Kit,
Q5 High Fidelity PCR Kit, endoglycosidase H (Endo H), and peptide-N-glycosidase F (PNGase F) were
obtained from New England Biolabs (NEB) (Ipswich, MA, USA). Superscript II was obtained from
Invitrogen (Carlsbad, CA, USA). TransIT-mRNA transfection reagent was obtained from Mirus Bio
(Madison, WI, USA). Oligonucleotide primers and probes for DNA amplification and qRT-PCR were
obtained from Sigma (St. Louis, MO, USA) and IDT (Coralville, IA, USA). mMESSAGE mMACHINE
T7 ULTRA Transcription Kit was from Ambion (Austin, TX, USA). Anti-flavivirus monoclonal antibody
D1-4G2-4-15 that reacts with ZIKV E protein was obtained from EMD Millipore (Billerica, MA, USA).
Rabbit polyclonal anti-NS1 antibody was obtained from GeneTex (Irvine, CA, USA). Mouse monoclonal
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antibody to GAPDH was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Secondary
antibodies were obtained from Sigma (St. Louis, MO, USA) and Invitrogen (Carlsbad, CA, USA).
2.4. qRT-PCR and Plaque Assay
Virus genome copy numbers in various tissue samples were determined by quantitative reverse
transcription and polymerase chain reaction (qRT-PCR), and infectious virus by plaque assay on
monolayers of Vero cells, as described previously [49].
2.5. Generation of Mutant Viruses
Mutant viruses were generated by site-directed mutagenesis of the previously described infectious
clone developed in our laboratory [49] using the primers described in Table 1. The asparagine residues at
130 and 207 of the NS1 protein were replaced with alanine residues either separately or in combination
(N130A, N207A, N130A, and N207A) in the background of m2MR virus [49], which lack E protein
glycosylation site (N154A). N130A mutant was generated with the use of the mutagenic primer 2
and the two outer primers 1 and 5; N207A mutant was generated using the mutagenic primer 3 and
the two outer primers 1 and 5; N130A/N207A double mutant was generated using the mutagenic
primers 2 and 4 and the outer primers 1 and 5. PCR amplified products were cloned into a full-length
infectious cDNA clone. Mutations were confirmed by sequencing of the clone. In vitro RNA transcripts
were synthesized from mutant cDNA clones using T7 RNA polymerase, as previously described [49].
Vero cells were transfected with RNA (~2 µg) using TransIT® -mRNA transfection kit, as per the
manufacturer’s recommendations. At five days post-transfection (dpt), immunofluorescence was
performed using 4G2 antibody targeting the E protein of ZIKV, as previously described [49]. For virus
recovery, CCSs were collected at 5–7 dpt, and the infectious virus yield was determined by plaque
assay on Vero cells.
Table 1. Primers used to generate non-structural protein 1 (NS1) glycosylation site mutants.
Primer and
Name

Sequence (5’ to 3’) *

Application

Nucleotide Change

1. MR-701F

GTGTACGGAACCTGTCATC

Upstream primer to generate
PCR product for cloning

2. NS1-130-N
to A-2864F

GCGGCAAAGACCGCCAAC
AGTTTTGTTGTC

N130A glycosylation mutation

AAC to GCC

3. NS1-207-N
to A-3090F

GGATTGAAAGTGAAAAG
GCTGACACATGGAG

Single (N207A) glycosylation
mutation

AAT to GCT

4. NS1-207-N
to A-3090R

CTCCATGTGTCAGCCTTTT
CACTTTCAATCC

Double (N130A/N207A)
glycosylation mutation

AAC to GCC and AAT
to GCT in reverse

5. MR-3873R

GCCAGGGCTAGCAGCA
TGCTCTCCCGCGGTGTCC
AATTGGC

Downstream primer to generate
PCR product for cloning

* Nucleotide sequences encoding the glycosylation sites are underlined. Sequences in bold-face represent NheI and
SacII sites in primer MR-3873R.

2.6. Mouse Experiments
Three- to four-week-old A129 mice (Ifnar1−/− ) were obtained from the Jackson Laboratory
(Bar Harbor, ME, USA). Initially, the animals were acclimatized for 4–5 days. The mice were injected
subcutaneously (s.c.) with PBS or 1000 PFU of rMR, or the mutant (m2MR and m5MR) viruses diluted
in 100 µL of PBS. For challenge studies, all the mice were injected s.c. with 10,000 PFU of rMR on
day 28 post-infection. For passive transfer experiment, the mice were injected s.c. with 200 µL of
heat-inactivated (56 ◦ C for 30 min) m5MR virus-infected mouse serum or naïve mouse serum as
control. Two hours post-transfer (hpt), mice were injected s.c. with 1000 PFU rMR virus and were
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monitored for disease signs twice daily. Change in body weight, disease signs, and survival was
recorded daily. We assigned scores for disease signs, as described previously [49]. Briefly, clinical
symptoms were scored as 0, Normal; 1, ruffled fur; 2, conjunctivitis, lethargy, hunched posture; 3,
one hind limb paralysis; 4, both hind limb paralysis; 5, all four limb paralysis; 6, moribund and
euthanization; 7, dead. Mice were considered as moribund when they appeared very lethargic, lost
more than 20% body weight, or showed limb paralysis and were euthanized. Blood was collected by
retro-orbital bleeding under anesthesia. Mice were euthanized by CO2 inhalation, and tissue samples
were collected. To assess the viral load in blood and tissues, we performed qRT-PCR for genome
copies and plaque assay for infectious viral titer. Tissues were examined for pathological changes
by histopathology. The qRT-PCR and histopathological evaluation were performed, as described
previously [49].
2.7. Plaque Reduction Neutralization Test
Plaque reduction neutralization test (PRNT) to measure ZIKV neutralizing antibody titers was
performed. Vero cells were plated in 12 well plates 24 h before infection to have confluency of 90–100%
at the time of infection. All serum samples were heat-inactivated at 56 ◦ C for 30 min prior testing.
The serum was diluted 1/100 followed by serial two-fold dilutions up to 1/12,800. Naïve mouse serum
served as the negative control in these studies. An equal volume of virus suspension containing ~200
PFU was mixed with diluted serum samples and incubated at 37 ◦ C for 1 h. After incubation, the
mixture was used to infect the cells in the plates at 37 ◦ C for 1 h with rocking every 10 min. Following
infection, the inoculum was removed, and the cells were overlaid with medium containing 1% low
gelling temperature (LGT) agarose in VGM as described for plaque assay. After incubation for 5 days
at 37 ◦ C, the plaques were counted manually. Antibody titers were determined as the reciprocal of the
serum dilution that inhibited 50% of the virus infectivity (PRNT50 ), and geometric mean titers (GMT)
were calculated from the PRNT50 values.
2.8. Western Blotting
For Western blotting, 8% polyacrylamide gel containing sodium dodecyl sulfate (SDS-PAGE)
was used. After electrophoresis, the proteins were transferred to polyvinylidene difluoride (PVDF)
membrane using a semi-dry transfer system (Bio-Rad, Hercules, CA, USA). The membrane was blocked
with blocking buffer (5% skim milk in tris-buffered saline (TBS) and 0.05% Tween 20) for 1–2 h. After
blocking the membrane, the specific primary antibody (anti-NS1 protein at 1:1000 dilution) was added
and incubated overnight at 4 ◦ C. The membrane was washed with TBS buffer containing 0.05% Tween
20 three times, 5–10 min each. Secondary antibody (Goat Anti-Rabbit HRP conjugated) at 1:5000
dilution was added and incubated for 1–2 h at room temperature. The membrane was washed with the
TBS buffer. Finally, the membrane was treated with Pierce™ ECL Western Blotting Substrate (Thermo
Fisher Scientific, Waltham, MA, USA) for 5 min and exposed to X-ray film or ChemiDoc Imaging
System (Bio-Rad, Hercules, CA, USA) for the required time to visualize the bands.
2.9. Acetone Precipitation of Proteins
For glycan analysis of NS1 proteins in the supernatants, Vero cells were infected with the
recombinant wt and mutant viruses at an MOI of 1 PFU/cell. The CCSs were collected at 2 dpi, and
proteins were concentrated by acetone precipitation. Briefly, one volume of CCS was mixed with
four-volume of cold acetone (−20 ◦ C) in a microcentrifuge tube and incubated for 60 min at −20 ◦ C.
The precipitated proteins were pelleted by centrifugation at 4 ◦ C for 10 min at 13,000–15,000× g.
The supernatant was discarded, and the pellet was air-dried at RT for 30 min. The pellet was
resuspended in 1X RIPA buffer with freshly added protease inhibitor cocktail (2 mM PMSF, 1 mM
Leupeptin). The proteins were digested with PNGase F as per manufacturer’s recommendations.
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2.10. Antibody Isotyping by ELISA
ELISA plates were coated with ZIKV envelope protein (#596088, MyBiosource, Inc., San Diego,
CA, USA) at 2 µg/mL in PBS for 16 h at 4 ◦ C. After addition in blocking buffer (Invitrogen, Superblock,
Thermo Fisher Scientific, Waltham, MA, USA serum samples diluted in blocking buffer (1:50) were
added and incubated at room temperature for 2 h. After removal of excess serum, biotinylated goat
anti-mouse IgG, biotinylated rat anti-mouse IgG1, or biotinylated rat anti-mouse IgG2a (Biolegend,
San Diego, CA, USA; catalog #405303, #406603, and #407103, respectively) were added in blocking
buffer at 1 µg/mL and incubated for 1 h. After three washes with PBS, streptavidin horseradish
peroxidase was added (1:1000; BD-Pharmingen, San Diego, CA, USA). After 30 min of incubation and
three washes with PBS, 3,3-,5,5-tetramethylbenzidine-hydrogen peroxide solution was added to each
well. IgG subclass specific anti-ZIKV envelope protein was measured by determining optical densities
at the 450-nm wavelength (OD450) with a reference OD570 using an ELISA plate reader.
2.11. ELISPOT Assay
The ZIKV T-cell epitopes were previously mapped, and the assay was performed, as described [51].
An overlapping peptide array of the ZIKV strain PRVABC59 E protein from BEI Resources (Catalog No.
NR-50553) was used. Peptides 1 and 2 (Table 2) were used for CD8+-specific response, whereas the
rest of the peptides were used for CD4+-specific response, as reported previously [51]. Ninety-six well
polyvinylidene difluoride-backed plates (MultiScreen-IP, Millipore, Burlington, MA, USA) were coated
with 50 µL of anti-mouse IFN-γ mAb AN18 (5 µg/mL; Mabtech, Cincinnati, OH, USA) overnight at 4 ◦ C.
Plates were washed and blocked with RPMI at 37 ◦ C for 1 h. Splenocytes were isolated from mice using
a 40 µm Nylon cell strainer (BD Labware, Franklin Lakes, NJ, USA), red blood cells were lysed using
ammonium chloride-potassium (ACK) lysis buffer, and the splenocytes were resuspended in complete
RPMI at a concentration of 4 × 106 cells/mL. The CD8 and CD4 peptide dilutions contained each
peptide at a concentration of 5 µg/mL. Equal volumes (50 µL) of the single-cell suspension splenocytes
and peptide dilutions were added to the wells in duplicate. Plates were incubated overnight at 37 ◦ C
with 5% CO2 , washed 6X with PBS, and incubated with 100 µL of biotinylated anti-mouse IFN-γ mAb
(1:1000 dilution; Mabtech) diluted in PBS with 1% FBS for 1 h at room temperature. Following washing
6X with PBS, the plates were incubated with 100 µL of streptavidin-alkaline phosphatase conjugate
(1:1000 dilution; Mabtech) diluted in PBS containing 1% FBS. After 1 h at room temperature, the plates
were washed 6x with PBS. To develop, 100 µL of 5-bromo-4-chloro-3’-indolyphosphate/nitro-blue
tetrazolium (BCIP/NBT) (Plus) alkaline phosphatase substrate (Thermo Fisher Scientific, Waltham, MA,
USA) was added to each well, and development was stopped by washing several times in distilled
water. The plates were air-dried, and spots were counted using an automated ELISPOT plate reader
(AID iSpot Reader Spectrum, Strassberg, France). Results are expressed as spot-forming cells (SFC) per
106 splenocytes.
2.12. Statistical Analysis
Data were analyzed using GraphPad Prism software version 6.0. Unpaired two-tailed Student’s
t-test, Mann–Whitney test, or Kruskal–Wallis test was performed for pairwise comparisons between
the groups to determine significant differences in viral loads (RNA levels, infectious titer), clinical
score, PRNT50 , ELISA, ELISPOT. Data were represented as either mean ± SEM or mean ± SD.
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Table 2. Peptides used for stimulation of T cells.
Peptide

Sequence *

Amino Acid Position in E (1–504)

1
2
3
6
8
19
21
24
25
102
103
104
119
120
123
124

IRCIGVSNRDFVEGM
IGVSNRDFVEGMSGG
SNRDFVEGMSGGTWV
SGGTWVDVVLEHGGC
DVVLEHGGCVTVMAQ
EVRSYCYEASISDMA
YEASISDMASDSRCP
SDSRCPTQGEAYLDK
RCPTQGEAYLDKQSD
SYSLCTAAFTFTKIP
LCTAAFTFTKIPAET
AAFTFTKIPAETLHG
VGRLITANPVITEST
LITANPVITESTENS
ESTENSKMMLELDPP
ENSKMMLELDPPFGD

1–15
4–18
7–21
16–30
22–36
55–69
61–75
70–84
73–87
304–318
307–321
310–324
355–369
358–372
367–381
370–384

* The peptide sequences specific to the ZIKV (Zika virus) envelope protein.

3. Results
3.1. Recovery and Characterization of E/NS1 Glycosylation Mutant Viruses
Our previous studies showed that mutant MR766 ZIKVs encoding non-glycosylated E protein
was highly attenuated in an immunodeficient mouse model [49]. Although the mutant virus-infected
animals showed no disease signs during the first six days, a small percentage (less than 10%) of the
animals exhibited mild signs of sickness, including weight loss and hind limb paralysis at 9 dpi,
but recovered completely without any further disease signs for up to 2 months. We hypothesized that
incorporation of glycosylation mutation in the NS1 in the background of E mutant virus would result in
more complete attenuation. Therefore, we generated three additional mutant viruses in the background
of the m2MR mutant virus, which encodes a non-glycosylated E protein, to study the effect of NS1
glycosylation in virus replication and pathogenesis. The asparagine residues in the glycosylation
sites in NS1 (N130 and N207) were changed to alanine residues in the genomic background of the
E glycosylation mutant virus (m2MR), and the mutant viruses (Figure 1A) (m3MR, with mutations
N154A in E and N130A in NS1; m4MR, with mutations N154A in E and N207A in NS1; m5MR with
mutations N154A in E, N130A and N207A in NS1) were recovered from the mutant infectious clones,
as described previously [49]. Interestingly and unlike the cells transfected with transcripts from m2MR,
m3MR, and m4MR clones, the cells transfected with RNA from m5MR clone showed localized foci of
fluorescence 6 days after transfection (Figure 1B), indicating a very restrictive growth of this virus.
Nevertheless, the m5MR virus could be readily recovered from the transfected cells. Multistep growth
kinetics studies revealed that the growth of single substitution NS1 mutant viruses (m3MR and m4MR)
was lower at 4 dpi in Vero cells, but they eventually grew to similar titers compared to m2MR virus by
6 to 7 dpi (Figure 1C). The double substitution NS1 mutant virus (m5MR), on the other hand, grew to
significantly lower titers at all-time points examined. In C6/36 mosquito cell line, both m3MR and
m4MR viruses grew to lower titers, while the m5MR virus grew to significantly lower titers at all times
examined compared to m2MR virus (Figure 1D). These results suggest that glycosylation of NS1 is
more important for the efficient growth of virus in mosquito cells than in Vero cells. Sequencing of
the E and NS1 coding region of the mutant viruses showed that all the mutant viruses retained the
engineered mutations after six passages in Vero cells, and no other mutations/deletions in the E and
NS1 protein-coding regions were observed.
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Figure 1.
1. Characterization
Characterizationofofthe
theenvelope
envelope(E)/non-structural
(E)/non-structuralprotein
protein11 (NS1)
(NS1) glycosylation
glycosylation mutant
mutant
Figure
viruses.
(A)
The
ZIKV
(Zika
virus)
genome
and
the
encoded
polyprotein,
showing
glycosylation
sites
viruses. (A) The ZIKV (Zika virus) genome and the encoded polyprotein, showing glycosylation
in E (N154) and NS1 (N130 and N207). The asparagine residue at each of these sites was mutated to
sites in E (N154) and NS1 (N130 and N207). The asparagine residue at each of these sites was
an alanine residue. (B) Two micrograms of in vitro transcribed RNA, from each of the mutant clones
mutated to an alanine residue. (B) Two micrograms of in vitro transcribed RNA, from each of the
or the wt(rMR) clone, were transfected into Vero cells in 6-well plates. After 5 days, the transfected
mutant clones or the wt(rMR) clone, were transfected into Vero cells in 6-well plates. After 5 days,
cells were processed for immunofluorescence staining using 4G2 monoclonal antibody to detect the
the transfected cells were processed for immunofluorescence staining using 4G2 monoclonal
E protein. Scale bar: 400 µm. Multistep growth of rMR, m2MR, m3MR, m4MR, and m5MR viruses
antibody to detect the E protein. Scale bar: 400 μm. Multistep growth of rMR, m2MR, m3MR,
in Vero (C) and C6/36 (D) cells. The data show mean values with error bars representing standard
m4MR, and m5MR viruses in Vero (C) and C6/36 (D) cells. The data show mean values with error
deviation from three independent experiments. Mann–Whitney test and Kruskal–Wallis test were used
bars representing standard deviation from three independent experiments. Mann–Whitney test and
to determine significance between m2MR and other mutant viruses at different times post-infection.
Kruskal–Wallis test were used to determine significance between m2MR and other mutant viruses
**, p < 0.01; *, p < 0.05; ns, non-significant.
at different times post-infection. **, p < 0.01; *, p < 0.05; ns, non-significant.

3.2. Glycosylation Status and Secretion of NS1 Protein from Mutant Virus-Infected Cells
3.2. Glycosylation Status and Secretion of NS1 Protein from Mutant Virus-Infected Cells
Since NS1 is secreted from cells infected with wild-type ZIKV, we examined the status of
Since
NS1ofisthe
secreted
from cells
wild-typefrom
ZIKV,
examined
the status
of
glycosylation
NS1 protein
and infected
whether with
it is secreted
the we
mutant
virus-infected
cells.
glycosylation
of
the
NS1
protein
and
whether
it
is
secreted
from
the
mutant
virus-infected
cells.
To
To address this, we infected Vero cells at an MOI of 1, and equal amounts of cell culture supernatants
address
infected
Vero cells atby
anacetone
MOI of precipitation
1, and equal and
amounts
cell
culture supernatants
collectedthis,
at 48we
dpi
were concentrated
eitherof
left
undigested
or digested
collected
at
48
dpi
were
concentrated
by
acetone
precipitation
and
either
left
undigested
or digested
with PNGase F (an enzyme that removes the glycan moiety from protein backbone) before
being
with
PNGase
F (an enzyme
the glycan
moiety
fromprotein
protein
backbone)
before being
analyzed
by Western
blotting that
usingremoves
an anti-NS1
antibody.
The NS1
from
m2MR virus-infected
analyzed
by Western
blotting
an anti-NS1 sites,
antibody.
The NS1migrated
protein faster
from(Figure
m2MR2,
cell supernatant,
which has
the twousing
intact glycosylation
upon digestion,
virus-infected
cell
supernatant,
which
has
the
two
intact
glycosylation
sites,
upon
digestion,
lane 4) than the undigested NS1 (lane 3). The NS1 from m3MR- or m4MR-infected supernatants, each
migrated
faster
(Figure
2, lane 4) site,
thanmigrated
the undigested
NS1 (lane
3).5 The
NS1
from
m3MR- or
of which has
a single
glycosylation
faster (Figure
2, lanes
and 7)
than
the undigested
m4MR-infected
supernatants,
each
of
which
has
a
single
glycosylation
site,
migrated
faster
2,
protein from the m2MR (lane 3) but slower than the corresponding digested proteins (lanes(Figure
6 and 8).
lanes
5
and
7)
than
the
undigested
protein
from
the
m2MR
(lane
3)
but
slower
than
the
On the other hand, no difference in migration of NS1 in undigested or digested m5MR-infected cell
corresponding digested proteins (lanes 6 and 8). On the other hand, no difference in migration of
NS1 in undigested or digested m5MR-infected cell supernatant was observed (Figure 2, lanes 9 and
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supernatant was observed (Figure 2, lanes 9 and 10), indicating that the NS1 protein produced from this
10), indicating that the NS1 protein produced from this virus-infected cells lacked PNGase F
virus-infected cells lacked PNGase F sensitive glycans. Although m3MR and m4MR viruses possessed
sensitive glycans. Although m3MR and m4MR viruses possessed single glycosylation site
single glycosylation site mutations, the NS1 proteins from m4MR-infected cell supernatant (lane 7)
mutations, the NS1 proteins from m4MR-infected cell supernatant (lane 7) migrated slower than that
migrated slower than that from m3MR-infected samples (lane 5), indicating that glycosylation at N130
from m3MR-infected samples (lane 5), indicating that glycosylation at N130 residue may be more
residue may be more complex and heterogeneous than glycosylation at residue N207. Furthermore,
complex and heterogeneous than glycosylation at residue N207. Furthermore, since NS1 was
since NS1 was secreted in significantly fewer amounts from m3MR- and m5MR-infected cells (lanes 5,
secreted in significantly fewer amounts from m3MR- and m5MR-infected cells (lanes 5, and 6, 9, and
and 6, 9, and 10) compared to m2MR- or m4MR-infected cells (lanes 3 and 4, 7 and 8), it appears that
10) compared to m2MR- or m4MR-infected cells (lanes 3 and 4, 7 and 8), it appears that glycosylation
glycosylation at N130 may be important for efficient secretion of NS1. However, a detailed quantitative
at N130 may be important for efficient secretion of NS1. However, a detailed quantitative analysis of
analysis of secreted and intracellular levels of each of these proteins would be necessary to strengthen
secreted and intracellular levels of each of these proteins would be necessary to strengthen such a
such a conclusion.
conclusion.

Figure
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secretionofof
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Figure 2.
NS1
protein
from
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virus-infected
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from an
equal volumewere
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concentrated
by acetone
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(−)
and
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using
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antibody.
Relative
migration
of
with PNGase F (+), or left undigested (−) and analyzed by Western blotting using anti-NS1 antibody.
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(in kDa)
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Relative
migration
of molecular
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(in kDa)
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effect
of nonglycosylation
both
the
E proteins
and NS1
proteins
on ZIKV
−/− A129 mice were divided into four groups: mock (n = 8),
in
animals,
three
to
four-week-old
Ifnar1
−/−
pathogenicity in animals, three to four-week-old Ifnar1 A129 mice were divided into four groups:
rMR (n(n==6),
12),
and m5MR
(n and
= 12).
Mice (n
were
inoculated
subcutaneously
(s.c.) with 1000
mock
8),m2MR
rMR (n(n==6),
m2MR
(n = 12),
m5MR
= 12).
Mice were
inoculated subcutaneously
PFU
of
the
virus
except
those
in
the
mock
group,
which
received
an
equal
volume
of
PBS.
Mice were
(s.c.) with 1000 PFU of the virus except those in the mock group, which received an equal volume
of
monitored
from
0
to
15
dpi
for
clinical
scores,
weight
loss,
and
survival,
and
viremia
in
the
first-week
PBS. Mice were monitored from 0 to 15 dpi for clinical scores, weight loss, and survival, and
viremia
post-infection
(Figure
3A). At 4–5
dpi,3A).
the At
rMR
started showing
disease
signs,
in
the first-week
post-infection
(Figure
4–5virus-infected
dpi, the rMR mice
virus-infected
mice started
showing
such
as
shivering,
conjunctivitis,
and
lethargy,
as
seen
previously
in
our
studies
[49].
Subsequently,
disease signs, such as shivering, conjunctivitis, and lethargy, as seen previously in our studies [49].
some mice showed
and hind
6–7 dpi, all
thebymice
Subsequently,
someboth
micefore
showed
bothlimb
foreparalysis,
and hindand
limbbyparalysis,
and
6–7 developed
dpi, all thesevere
mice
disease
signs
and
had
to
be
euthanized.
In
contrast,
mice
in
the
m2MR
and
m5MR
groups
showed
no
developed severe disease signs and had to be euthanized. In contrast, mice in the m2MR and m5MR
symptoms
at
6
dpi
(Figure
3B).
However,
at
8–10
dpi,
two
to
three
mice
from
m2MR
group
showed
groups showed no symptoms at 6 dpi (Figure 3B). However, at 8–10 dpi, two to three mice from
mild paralysis,
but most
of them
recovered
by 11of
dpi.
Interestingly,
all mice
in the
m5MR virus-infected
m2MR
group showed
mild
paralysis,
but most
them
recovered by
11 dpi.
Interestingly,
all mice in
group
did
not
show
any
disease
signs
between
0–15
dpi
(Figure
3C).
The
rMR
virus-infected
the m5MR virus-infected group did not show any disease signs between 0–15 dpi
(Figure 3C).mice
The
exhibited
a weight loss
more thana 20%
by 6loss
dpiof(Figure
died
by were
7 dpi
rMR
virus-infected
miceofexhibited
weight
more 3D)
thanand
20%were
by 6euthanized
dpi (Figureor3D)
and
(Figure 3E). or
Mice
in by
the7m2MR
group3E).
showed
weight
while
those mild
in theweight
m5MRloss,
group
and
euthanized
died
dpi (Figure
Mice mild
in the
m2MRloss,
group
showed
while
the
PBS-inoculated
control
group
exhibited
no
weight
loss
(Figure
3D).
Only
one
animal
in
the
m2MR
those in the m5MR group and the PBS-inoculated control group exhibited no weight loss (Figure
infected
was moribund
and,infected
thus, euthanized
3E). and,
Furthermore,
survived(Figure
mice from
3D).
Onlygroup
one animal
in the m2MR
group was(Figure
moribund
thus, euthanized
3E).
m2MR
group
or
all
mice
from
m5MR
group
did
not
show
any
weight
loss,
disease
signs,
or
mortality
Furthermore, survived mice from m2MR group or all mice from m5MR group did not show any
until challenge
at 28signs,
dpi. or
Viral
genome
copy
numbers
dpiViral
weregenome
highest copy
in rMR
virus-infected
weight
loss, disease
mortality
until
challenge
atat
283dpi.
numbers
at 3 dpi
animals,
whereas
the
m2MR
and
m5MR
groups
showed
~10–15-fold
and
~1000-fold
reductions,
were highest in rMR virus-infected animals, whereas the m2MR and m5MR groups showed ~10–
respectively,
compared reductions,
to mice in the
rMR group
(Figure 3F).
However,
6 dpi,
rMR(Figure
and m2MR
15-fold
and ~1000-fold
respectively,
compared
to mice
in theatrMR
group
3F).
infected
animals
showed
a
similar
number
of
viral
genome
copies
in
blood.
In
contrast,
thegenome
m5MR
However, at 6 dpi, rMR and m2MR infected animals showed a similar number of viral

copies in blood. In contrast, the m5MR group showed significantly lower levels of viremia (Figure
3F). Infectious viral titers showed a similar trend as genome copies at 3 dpi and 6 dpi (Figure 3G).
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Figure3.
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and
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in
−/− A129 mice. Mice were injected subcutaneously (s.c.) with 1000
in
three
to
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three to four-week-old Ifnar1 −/− A129 mice. Mice were injected subcutaneously (s.c.) with 1000 PFU
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(D) Weight
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presented are combined data from two independent experiments. Unpaired Student’s t-test
(B,C)) and Mann–Whitney test (for panel (F,G)) were used to determine significance between groups.
(two-tailed) (for panel (B,C)) and Mann–Whitney test (for panel (F,G)) were used to determine
****, p < 0.0001; ***, p < 0.001; **, p < 0.01; ns, non-significant.
significance between groups. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; ns, non-significant.

To measure viral replication and examine pathology in tissues, we sacrificed several mice from each
To measure viral replication and examine pathology in tissues, we sacrificed several mice from
group and collected tissues at 6 dpi. Viral genome copies in the brain of m2MR- and m5MR-infected
each group and collected tissues at 6 dpi. Viral genome copies in the brain of m2MR- and
mice were significantly lower compared to the rMR-infected mice (Figure 4A). The m5MR-infected
m5MR-infected mice were significantly lower compared to the rMR-infected mice (Figure 4A). The
mice had significantly lower genome copies (~90-fold less) as compared to those infected with m2MR
m5MR-infected mice had significantly lower genome copies (~90-fold less) as compared to those
virus (Figure 4A). Infectious viral titer in the brain followed a similar pattern between the groups
infected with m2MR virus (Figure 4A). Infectious viral titer in the brain followed a similar pattern
(Figure 4B). Although replication of the m5MR virus in the brain was significantly restricted, the virus
between the groups (Figure 4B). Although replication of the m5MR virus in the brain was
replicated to moderate levels in other tissues, such as spleen and liver. m5MR virus replicated six- to
significantly restricted, the virus replicated to moderate levels in other tissues, such as spleen and
ten-fold less in these tissues compared to rMR and m2MR virus-infected mice (Figure 4C,D). Overall,
liver. m5MR virus replicated six- to ten-fold less in these tissues compared to rMR and m2MR
these results indicate that m5MR virus replication is severely restricted in the brain and to some extent
virus-infected mice (Figure 4C, D). Overall, these results indicate that m5MR virus replication is
in the spleen and liver of the infected animals.
severely restricted in the brain and to some extent in the spleen and liver of the infected animals.
Histopathological examination of tissues corroborated the findings from the viral load. The
brain sections of mice from the rMR-infected group showed generalized moderate to severe
perivascular cuffing, which predominantly contained mononuclear cells with occasional neutrophils
(Figure 4E). The meninges showed lymphocytic perivascular cuffing. Shrunken hyperchromatic
neurons and occasional karyorrhectic cells were seen in the brains of rMR-infected mice. Brains in
the m2MR group showed rare diffuse mild cuffing in the parenchyma along with occasional
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shrunken hyperchromatic neurons (Figure 4E). In contrast, perivascular cuffing in the brain
11 of 21
m5MR-infected mice was rare (Figure 4E), while the meninges appeared normal,
which was very similar to the brains of mice in the PBS injected group.
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Histopathological examination of tissues corroborated the findings from the viral load. The brain
sections
micevirus-infected
from the rMR-infected
group
showed
generalized
to severe
perivascular
In of
rMR
mice, the
spleen
exhibited
mildmoderate
lymphoid
hyperplasia
with
cuffing,
which
predominantly
contained
mononuclear
cells
with
occasional
neutrophils
(Figure
4E).
hypertrophied lymphocytes and occasional aggregates of neutrophils. Diffuse karyorrhexis
was also
The
meninges
showedwhereas
lymphocytic
perivascular
cuffing.
hyperchromatic
neurons
and
noted
in the spleen,
the liver
showed few
smallShrunken
mononuclear
cell foci and
prominent
occasional
karyorrhectic
cells
were
seen
in
the
brains
of
rMR-infected
mice.
Brains
in
the
m2MR
group
Kupffer cells, similar to our previous observations [49]. Overall, the pathological changes in the
showed
rareliver
diffuse
mild cuffing in the
along
with occasional
hyperchromatic
spleen and
of m5MR-infected
miceparenchyma
were minimal
compared
to those shrunken
in the other
virus-infected
neurons
(Figure
4E).
In
contrast,
perivascular
cuffing
in
the
brain
parenchyma
of
m5MR-infected
mice
groups.
was rare (Figure 4E), while the meninges appeared normal, which was very similar to the brains of
mice in the PBS injected group.
In rMR virus-infected mice, the spleen exhibited mild lymphoid hyperplasia with hypertrophied
lymphocytes and occasional aggregates of neutrophils. Diffuse karyorrhexis was also noted in the
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spleen, whereas the liver showed few small mononuclear cell foci and prominent Kupffer cells,
similar
to our
Vaccines 2019,
7, xprevious observations [49]. Overall, the pathological changes in the spleen and liver
12 of of
21
m5MR-infected mice were minimal compared to those in the other virus-infected groups.
3.4. m5MR Virus Protects Immunocompromised Mice from Lethal Challenge
3.4. m5MR Virus Protects Immunocompromised Mice from Lethal Challenge
The majority of mice in the m2MR-infected group and all mice in the m5MR-infected group
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whereas
weight loss after challenge, whereas mild weight loss was observed in m2MR group and no weight
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was(Figure
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in m2MR group and no weight loss in m5MR group (Figure 5B).
loss in
m5MR
group
5B).
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Interestingly, all mice in the m5MR group survived the challenge, whereas 80% of mice in the
m2MR
group and none
in the
PBSm5MR
control
group
survived
challengewhereas
(Figure80%
5C). of
Additionally,
Interestingly,
all mice
in the
group
survived
thethe
challenge,
mice in the
we
observed
2
log
lower
levels
of
challenge
virus
(rMR)
viremia
in
m2MR-infected
animals
compared
m2MR group and none in the PBS control group survived the challenge (Figure 5C). Additionally,
to
control 2group
and undetectable
levels of virus
challenge
virus
(rMR) in
viremia
in m5MR-infected
wePBS
observed
log lower
levels of challenge
(rMR)
viremia
m2MR-infected
animals

compared to PBS control group and undetectable levels of challenge virus (rMR) viremia in
m5MR-infected animals following challenge (Figure 5D). Overall, the results show that the m5MR
virus-infected animals were fully protected upon lethal virus challenge, whereas mice in m2MR
group were partially protected compared to the m5MR group. These results suggest that protective
immune responses were induced in these animals by the m5MR and m2MR viruses.
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3.6. Passive Transfer of Antibodies from Animals Infected with m5MR Virus Protects Mice from Lethal
Challenge
To determine if the serum from m5MR virus-infected mice could confer protection against
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3.6. Passive Transfer of Antibodies from Animals Infected with m5MR Virus Protects Mice from
Lethal Challenge
To determine if the serum from m5MR virus-infected mice could confer protection against lethal
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MEX1–7 strains of ZIKV. Our results showed high neutralization titers against PRVABC59 (GMT:
6142) and MEX 1-7 (GMT: 5339) strains (Figure 7E), similar to that observed for MR766 strain (Figure
6A). These results suggest that m5MR virus immune sera may confer heterologous protection.
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MEX1–7 strains of ZIKV. Our results showed high neutralization titers against PRVABC59 (GMT: 6142)
and MEX 1-7 (GMT: 5339) strains (Figure 7E), similar to that observed for MR766 strain (Figure 6A).
These results suggest that m5MR virus immune sera may confer heterologous protection.
4. Discussion
The recent emergence of ZIKV in the western hemisphere and the association of ZIKV with
congenital malformations, such as microcephaly and Guillain-Barré syndrome, have raised a serious
public health concern. To date, no clinically approved drugs or vaccines are available for ZIKV
infection. Several vaccine platforms are being developed for ZIKV [54–56], and other flavivirus vaccine
strategies are also being applied to ZIKV [57]. Platforms, such as inactivated and subunit vaccines,
have shown to be effective in mice and nonhuman primate models [58–60] but none of them have been
approved for clinical use as yet. Since live attenuated virus vaccines can often provide long-lasting
protection with a single dose without the additional need for adjuvants or other carrier proteins, these
platforms have significant advantages over subunit or killed vaccine strategies. Attenuation strategies
through genetic manipulation of infectious clones have been employed for YFV, Japanese encephalitis
virus (JEV), WNV, DENV-2, and DENV-4 virus, as well as ZIKV [39,42,55,61–63]. We and others had
previously shown that a mutant ZIKV containing a single amino acid substitution (N154A) in the E
protein glycosylation site was attenuated in pathogenicity and neuroinvasion [49,64,65]. Additionally,
ZIKV encoding mutant NS1 protein without glycosylation has been shown to confer protection against
fetal transmission [63]. Here, we attempted to further attenuate the pathogenicity of the virus by
incorporating glycosylation site mutations in the NS1 protein in the genomic background of a virus
with E glycosylation mutation (m2MR virus). Using the newly generated virus (m5MR) encoding
non-glycosylated E and NS1 proteins, our results showed that the m5MR virus was stable, replicated
less efficiently in cell culture, particularly in mosquito cells (C6/36) compared to the wildtype rMR
virus, displayed complete attenuated phenotype in mice model, and exhibited mild to no pathology
in tissues of infected animals. Also, m5MR virus protected animals from lethal challenge with rMR
virus by eliciting strong humoral and cellular immune responses. Importantly, passive transfer of
m5MR-infected mice sera completely protected the immunocompromised mice upon lethal rMR
virus challenge.
In our effort to determine the role of the two conserved NS1 glycosylation sites in replication and
pathogenesis, we generated three mutant viruses by mutating the sites (N130 and N207) individually or
together in the background of E protein glycosylation mutant virus. All the mutant viruses were found
to be genetically stable under in vitro growth conditions as they retained the engineered mutations
and revealed no additional nucleotide changes in the E and NS1 protein-coding sequences upon six
passages in cell culture. On the other hand, such mutations in the NS1 glycosylation sites (N130 and
N207) in DENV-2 led to virus instability, with multiple mutations in NS1 region arising after one
passage in cells [45]. Whether mutant ZIKVs containing glycosylation mutations in both E and NS1
proteins are more stable than the DENV-2 mutant viruses carrying only the NS1 mutations or whether
compensating mutations in other viral protein-coding regions are present in m5MR virus is not known
at this time but could be investigated in the future. It should also be noted that unlike stable genotype
of the m5MR virus mutant, a recent study described that PRVABC59 ZIKV and its infectious clone
quickly accumulate stable mutations in E and NS1 proteins in mice, resulting in their attenuation of
pathogenicity [66]. It is unclear at this time whether the sequence stability of our m5MR virus is related
to the virus strain and the conditions of passage or that the PRVABC59 virus is more prone to sequence
changes when passaged in mice.
Examination of growth kinetics of the mutant viruses (m3MR, m4MR, and m5MR) in Vero and
C6/36 cells revealed that glycosylation at each of the NS1 sites was required for efficient viral growth.
Although m3MR and m4MR viruses grew to somewhat lower titers in these cells, the growth of m5MR
virus was significantly inhibited. This is particularly true for m5MR virus growth in C6/36 mosquito
cells in which the virus grew to significantly reduced titers. The localized foci of E-expressing cells
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during virus recovery after RNA transfection (Figure 1B) are also particularly noteworthy. Inefficient
secretion of a nonglycosylated NS1 protein might be responsible for this phenotype. In this regard,
it will be interesting to examine if replication and transmission of the m5MR virus are negatively
impacted by mosquito vectors.
Examination of the mobility differences between the NS1 proteins of m3MR and m4MR viruses
suggested that N130 and N207 glycosylation sites might contain different glycan moieties. The NS1
of m3MR virus migrated slightly faster than that of the m4MR virus, indicating that sugar moiety at
N130 might be larger and/or more complex than the moiety at N207. These results are consistent with
previous observations from other closely related flaviviruses, showing that NS1 N130 has a complex
glycan moiety and N207 contains high-mannose sugar moiety [29,32]. Although we had not conducted
a thorough and quantitative determination of NS1 secretion and its glycosylation status, it appeared
from our results, presented in Figure 2, that efficient secretion of NS1 required glycosylation at N130
residue whereas glycosylation at N207 did not have a significant impact on secretion. Our results with
ZIKV are consistent with other related viruses, such as DENV, WNV, and YFV, showing that mutations
in glycosylation sites of NS1 affect its hexamer stability and secretion [28,39,40,47,48].
The results presented here demonstrated the effects of NS1 glycosylation on ZIKV replication and
pathogenesis. This was borne out from our observation of not only reduced growth and replication of
the m5MR virus in cultured cells but also the absence of any disease signs or disease in susceptible
mice. The difference in mean viral loads between m5MR and m2MR virus-infected mice in the brain
(Figure 4A) suggested that ZIKV attenuation was influenced by the glycosylation status of the NS1
protein. It has been proposed that ZIKV NS1 may interact with the endothelial cells of the blood-brain
barrier (BBB) and maternal/fetal interface, favoring viral entry into the brain and fetus, respectively [67].
It is possible that the nonglycosylated NS1 produced in m5MR-infected mice may not interact efficiently
with endothelial cells. Additionally, the reduced rate of secretion of nonglycosylated NS1 may also
contribute to the nonpathogenic property of the m5MR virus. Mild to no histopathological changes in
the brain further strengthens our suggestion for the benign nature of the m5MR virus infection.
Interestingly, the protection afforded by m5MR from rMR virus challenge is an important finding
because the m5MR virus completely protected (100% survival) mice. Therefore, the m5MR virus
could be potentially used as a live attenuated vaccine to induce protective immune responses against
ZIKV. The increased levels of IgG2a antibodies in m5MR-infected mice indicate that Th1 type immune
responses likely contribute to protection. Studies have shown that the Th1 type immune response
stimulates IgG antibody subclasses that are important for mediating antibody dependent cellular
cytotoxicity (ADCC) and complement activities in mice [20,68,69]. It is possible that upon rMR virus
challenge, virus-infected cells present viral protein antigens on the cell surface, which are then targeted
by IgG2a antibodies followed by recruitment of lymphoid cells bearing Fc-γ receptors, to kill infected
cells by ADCC [19,20]. The importance of antibodies in protecting immunodeficient mice against
WNV infection has been reported [70]. Since antibodies to NS1 protein of ZIKV and other flaviviruses
are protective [4,19,23], it is also possible that the induction of antibodies against unglycosylated NS1
protein in m5MR virus-infected animals may be protective.
Increased levels of CD8+ and CD4+ T cells in the m5MR-infected group are indicative of robust
cellular immune responses. The strong CD8+ T cell response in m5MR-infected animals, most likely
contributed to the clearance of virus from the blood and organs upon challenge, which is confirmed by
lack of virus detection in plasma and tissues at 3 dpi and 6 dpi, respectively, after rMR virus challenge.
Similar clearance of the virus from the brain after the intracranial challenge of the virus was earlier
reported for ZIKV, and it was hypothesized that the CD8+ T cell response was the contributing factor
for clearance [69]. Furthermore, it was shown previously that CD8+ T cells contribute to clearance
of virus from tissues in WNV-infected mice by inducing death of the virus-infected cells, which
express WNV epitopes with class I MHC molecules on the cell surface [71]. Our observations of
strong neutralizing antibody response, as well as T cells responses, suggest that the antibody response,
in addition to protecting mice from the initial virus infection, may have augmented viral clearance,
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while the cell-mediated immunity, particularly CD8+ T cells, may have been responsible for clearing
the virus from the tissues by inducing virus-infected cell death. Indeed, it has been shown that both
B and T cells are needed to restrict ZIKV infection in IFN-knockout immunocompromised mice [72].
Future studies involving the adoptive transfer of T cells to naïve animals and subsequent challenge
experiments may reveal the extent of the role of T cells in protection.
Given the high conservation of E and NS1 proteins among ZIKV isolates, the m5MR virus should
be protective against most or all ZIKV strains and could potentially serve as a universal vaccine
candidate. Although our protection studies did not include heterologous strains for the challenge,
the results from in vitro antibody neutralization studies with other strains of Asian lineage viruses
suggest that the protection afforded by m5MR virus could be extended to multiple ZIKV strains,
as the antigenic structures among ZIKVs are similar [16,69]. For example, studies have shown that
human convalescent sera equally neutralize different ZIKV strains [60]. Thus, it would be interesting
to examine the protection conferred by m5MR virus to challenge with heterologous strains of ZIKV.
With regard to m5MR virus as a vaccine candidate, the stability of passage 6 m5MR virus in Vero
cells is significant, as Vero cells are the approved cell line for vaccine production with 5 days per
passage [73,74], which is also similar with other live vaccine candidates for ZIKV [75].
5. Conclusions
Results presented here showed that a recombinant ZIKV (m5MR) encoding non-glycosylated E,
as well as non-glycosylated NS1 proteins, exhibited a highly attenuated phenotype, induced higher
levels of humoral and cell-mediated immune responses, and conferred complete protection against
lethal challenge. Thus, m5MR virus could serve as a potential live viral vaccine candidate.
Author Contributions: Conceptualization: A.S.A. and A.K.P.; Methodology: A.S.A., A.P., B.R.S., Z.P.G., B.L.B. and
D.S.; Formal analysis: A.S.A., A.P., B.R.S., Z.P.G., B.L.B., D.S. and A.K.P.; Investigation: A.S.A. and A.K.P.; Resource:
E.A.W., S.K.N., T.M.P. and A.K.P.; Data Curation: A.S.A., A.P., B.R.S., Z.P.G., B.L.B. and A.K.P.; Writing-Original
Draft Preparation: A.S.A., A.P., B.R.S., Z.P.G., B.L.B. and A.K.P.; Writing-Review and Editing: A.S.A., A.P., B.R.S.,
E.A.W., S.K.N., T.M.P. and A.K.P.; Supervision: A.K.P.; Project Administration: A.K.P.; Funding Acquisition: A.K.P.
Funding: The research was supported in part by funds from the University of Nebraska-Lincoln.
Acknowledgments: We thank BEI Resources for E protein-peptide array, Catalog # NR-50553.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.

2.
3.
4.

5.

6.

7.

Hills, S.L.; Russell, K.; Hennessey, M.; Williams, C.; Oster, A.M.; Fischer, M.; Mead, P. Transmission of Zika
Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission—Continental United States,
2016. MMWR Morb. Mortal. Wkly. Rep. 2016, 65, 215–216. [CrossRef] [PubMed]
Musso, D.; Gubler, D.J. Zika Virus. Clin. Microbiol. Rev. 2016, 29, 487–524. [CrossRef] [PubMed]
Sharma, A.; Lal, S.K. Zika Virus: Transmission, Detection, Control, and Prevention. Front. Microbiol. 2017, 8,
110. [CrossRef] [PubMed]
Bailey, M.J.; Duehr, J.; Dulin, H.; Broecker, F.; Brown, J.A.; Arumemi, F.O.; Bermudez Gonzalez, M.C.;
Leyva-Grado, V.H.; Evans, M.J.; Simon, V.; et al. Human antibodies targeting Zika virus NS1 provide
protection against disease in a mouse model. Nat. Commun. 2018, 9, 4560. [CrossRef]
Bogoch, I.I.; Brady, O.J.; Kraemer, M.U.G.; German, M.; Creatore, M.I.; Kulkarni, M.A.; Brownstein, J.S.;
Mekaru, S.R.; Hay, S.I.; Groot, E.; et al. Anticipating the international spread of Zika virus from Brazil. Lancet
2016, 387, 335–336. [CrossRef]
Ladhani, S.N.; O’Connor, C.; Kirkbride, H.; Brooks, T.; Morgan, D. Outbreak of Zika virus disease in the
Americas and the association with microcephaly, congenital malformations and Guillain-Barre syndrome.
Arch. Dis. Child. 2016, 101, 600–602. [CrossRef]
Carod-Artal, F.J. Neurological complications of Zika virus infection. Expert Rev. Anti Infect. Ther. 2018, 16,
399–410. [CrossRef]

Vaccines 2019, 7, 112

8.
9.
10.
11.

12.
13.

14.

15.
16.

17.

18.

19.
20.

21.

22.

23.
24.

25.
26.
27.
28.

18 of 21

Coyne, C.B.; Lazear, H.M. Zika virus—Reigniting the TORCH. Nat. Rev. Microbiol. 2016, 14, 707–715.
[CrossRef] [PubMed]
Van Hemert, F.; Berkhout, B. Nucleotide composition of the Zika virus RNA genome and its codon usage.
Virol. J. 2016, 13, 95. [CrossRef]
Kuno, G.; Chang, G.J. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika
viruses. Arch. Virol. 2007, 152, 687–696. [CrossRef]
Lindenbach, B.D.; Murray, C.L.; Thiel, R.J.; Rice, C.M. Flaviviridae, 6th ed.; Knipe, D.M., Howley, P.M.,
Cohen, J.I., Grifin, D.E., Lamb, R.A., Martin, M.A., Recaniello, V.R., Roizman, B., Eds.; Lippincott Williams
and Wilkins: Philadelphia, PA, USA, 2013.
Diamond, M.S.; Pierson, T.C. Molecular Insight into Dengue Virus Pathogenesis and Its Implications for
Disease Control. Cell 2015, 162, 488–492. [CrossRef] [PubMed]
Grant, A.; Ponia, S.S.; Tripathi, S.; Balasubramaniam, V.; Miorin, L.; Sourisseau, M.; Schwarz, M.C.;
Sanchez-Seco, M.P.; Evans, M.J.; Best, S.M.; et al. Zika Virus Targets Human STAT2 to Inhibit Type I Interferon
Signaling. Cell Host Microbe 2016, 19, 882–890. [CrossRef] [PubMed]
Kumar, A.; Hou, S.; Airo, A.M.; Limonta, D.; Mancinelli, V.; Branton, W.; Power, C.; Hobman, T.C. Zika virus
inhibits type-I interferon production and downstream signaling. EMBO Rep. 2016, 17, 1766–1775. [CrossRef]
[PubMed]
Dai, L.; Wang, Q.; Song, H.; Gao, G.F. Zika Virus Envelope Protein and Antibody Complexes. Subcell Biochem.
2018, 88, 147–168. [PubMed]
Heinz, F.X.; Stiasny, K. The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses:
Implications for Infection and Immunoprophylaxis. Microbiol. Mol. Biol. Rev. MMBR 2017, 81, e00055-16.
[CrossRef] [PubMed]
Barba-Spaeth, G.; Dejnirattisai, W.; Rouvinski, A.; Vaney, M.C.; Medits, I.; Sharma, A.; Simon-Loriere, E.;
Sakuntabhai, A.; Cao-Lormeau, V.M.; Haouz, A.; et al. Structural basis of potent Zika-dengue virus antibody
cross-neutralization. Nature 2016, 536, 48–53. [CrossRef] [PubMed]
Stettler, K.; Beltramello, M.; Espinosa, D.A.; Graham, V.; Cassotta, A.; Bianchi, S.; Vanzetta, F.; Minola, A.;
Jaconi, S.; Mele, F.; et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.
Science 2016, 353, 823–826. [CrossRef]
Schlesinger, J.J.; Foltzer, M.; Chapman, S. The Fc portion of antibody to yellow fever virus NS1 is a determinant
of protection against YF encephalitis in mice. Virology 1993, 192, 132–141. [CrossRef]
Chung, K.M.; Thompson, B.S.; Fremont, D.H.; Diamond, M.S. Antibody recognition of cell surface-associated
NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells.
J. Virol. 2007, 81, 9551–9555. [CrossRef]
Chung, K.M.; Liszewski, M.K.; Nybakken, G.; Davis, A.E.; Townsend, R.R.; Fremont, D.H.; Atkinson, J.P.;
Diamond, M.S. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the
regulatory protein factor H. Proc. Natl. Acad. Sci. USA 2006, 103, 19111–19116. [CrossRef]
Li, A.; Yu, J.; Lu, M.; Ma, Y.; Attia, Z.; Shan, C.; Xue, M.; Liang, X.; Craig, K.; Makadiya, N.; et al. A Zika
virus vaccine expressing premembrane-envelope-NS1 polyprotein. Nat. Commun. 2018, 9, 3067. [CrossRef]
[PubMed]
Bailey, M.J.; Broecker, F.; Duehr, J.; Arumemi, F.; Krammer, F.; Palese, P.; Tan, G.S. Antibodies Elicited by an
NS1-Based Vaccine Protect Mice against Zika Virus. mBio 2019, 10. [CrossRef] [PubMed]
Watanabe, S.; Tan, K.H.; Rathore, A.P.; Rozen-Gagnon, K.; Shuai, W.; Ruedl, C.; Vasudevan, S.G. The magnitude
of dengue virus NS1 protein secretion is strain dependent and does not correlate with severe pathologies in
the mouse infection model. J. Virol. 2012, 86, 5508–5514. [CrossRef] [PubMed]
Rastogi, M.; Sharma, N.; Singh, S.K. Flavivirus NS1: A multifaceted enigmatic viral protein. Virol. J. 2016, 13,
131. [CrossRef] [PubMed]
Watterson, D.; Modhiran, N.; Young, P.R. The many faces of the flavivirus NS1 protein offer a multitude of
options for inhibitor design. Antivir. Res. 2016, 130, 7–18. [CrossRef]
Westaway, E.G.; Goodman, M.R. Variation in distribution of the three flavivirus-specified glycoproteins
detected by immunofluorescence in infected Vero cells. Arch. Virol. 1987, 94, 215–228. [CrossRef]
Flamand, M.; Megret, F.; Mathieu, M.; Lepault, J.; Rey, F.A.; Deubel, V. Dengue virus type 1 nonstructural
glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent
fashion. J. Virol. 1999, 73, 6104–6110. [PubMed]

Vaccines 2019, 7, 112

29.
30.
31.

32.
33.

34.

35.

36.

37.
38.

39.

40.
41.
42.

43.
44.

45.
46.
47.

48.

19 of 21

Muller, D.A.; Young, P.R. The flavivirus NS1 protein: Molecular and structural biology, immunology, role in
pathogenesis and application as a diagnostic biomarker. Antivir. Res. 2013, 98, 192–208. [CrossRef] [PubMed]
Mackenzie, J.M.; Jones, M.K.; Young, P.R. Immunolocalization of the dengue virus nonstructural glycoprotein
NS1 suggests a role in viral RNA replication. Virology 1996, 220, 232–240. [CrossRef]
Westaway, E.G.; Mackenzie, J.M.; Kenney, M.T.; Jones, M.K.; Khromykh, A.A. Ultrastructure of Kunjin
virus-infected cells: Colocalization of NS1 and NS3 with double-stranded RNA, and of NS2B with NS3,
in virus-induced membrane structures. J. Virol. 1997, 71, 6650–6661. [PubMed]
Yap, S.S.L.; Nguyen-Khuong, T.; Rudd, P.M.; Alonso, S. Dengue Virus Glycosylation: What Do We Know?
Front. Microbiol. 2017, 8, 1415. [CrossRef] [PubMed]
Crooks, A.J.; Lee, J.M.; Dowsett, A.B.; Stephenson, J.R. Purification and analysis of infectious virions and
native non-structural antigens from cells infected with tick-borne encephalitis virus. J. Chromatogr. 1990, 502,
59–68. [CrossRef]
Avirutnan, P.; Fuchs, A.; Hauhart, R.E.; Somnuke, P.; Youn, S.; Diamond, M.S.; Atkinson, J.P. Antagonism of
the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 2010, 207, 793–806.
[CrossRef] [PubMed]
Avirutnan, P.; Punyadee, N.; Noisakran, S.; Komoltri, C.; Thiemmeca, S.; Auethavornanan, K.; Jairungsri, A.;
Kanlaya, R.; Tangthawornchaikul, N.; Puttikhunt, C.; et al. Vascular leakage in severe dengue virus infections:
A potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 2006, 193, 1078–1088.
[CrossRef] [PubMed]
Dalgarno, L.; Trent, D.W.; Strauss, J.H.; Rice, C.M. Partial nucleotide sequence of the Murray Valley
encephalitis virus genome. Comparison of the encoded polypeptides with yellow fever virus structural and
non-structural proteins. J. Mol. Biol. 1986, 187, 309–323. [CrossRef]
Naik, N.G.; Wu, H.N. Mutation of Putative N-Glycosylation Sites on Dengue Virus NS4B Decreases RNA
Replication. J. Virol. 2015, 89, 6746–6760. [CrossRef] [PubMed]
Kim, J.M.; Yun, S.I.; Song, B.H.; Hahn, Y.S.; Lee, C.H.; Oh, H.W.; Lee, Y.M. A single N-linked glycosylation
site in the Japanese encephalitis virus prM protein is critical for cell type-specific prM protein biogenesis,
virus particle release, and pathogenicity in mice. J. Virol. 2008, 82, 7846–7862. [CrossRef]
Somnuke, P.; Hauhart, R.E.; Atkinson, J.P.; Diamond, M.S.; Avirutnan, P. N-linked glycosylation of dengue
virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with
human complement. Virology 2011, 413, 253–264. [CrossRef] [PubMed]
Pryor, M.J.; Wright, P.J. Glycosylation mutants of dengue virus NS1 protein. J. Gen. Virol. 1994, 75 Pt 5,
1183–1187. [CrossRef]
Flamand, M.; Deubel, V.; Girard, M. Expression and secretion of Japanese encephalitis virus nonstructural
protein NS1 by insect cells using a recombinant baculovirus. Virology 1992, 191, 826–836. [CrossRef]
Whiteman, M.C.; Li, L.; Wicker, J.A.; Kinney, R.M.; Huang, C.; Beasley, D.W.; Chung, K.M.; Diamond, M.S.;
Solomon, T.; Barrett, A.D. Development and characterization of non-glycosylated E and NS1 mutant viruses
as a potential candidate vaccine for West Nile virus. Vaccine 2010, 28, 1075–1083. [CrossRef] [PubMed]
Sirohi, D.; Chen, Z.; Sun, L.; Klose, T.; Pierson, T.C.; Rossmann, M.G.; Kuhn, R.J. The 3.8 A resolution cryo-EM
structure of Zika virus. Science 2016, 352, 467–470. [CrossRef] [PubMed]
Xu, X.; Song, H.; Qi, J.; Liu, Y.; Wang, H.; Su, C.; Shi, Y.; Gao, G.F. Contribution of intertwined loop to
membrane association revealed by Zika virus full-length NS1 structure. EMBO J. 2016, 35, 2170–2178.
[CrossRef] [PubMed]
Crabtree, M.B.; Kinney, R.M.; Miller, B.R. Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681:
Construction and characterization of mutant viruses. Arch. Virol. 2005, 150, 771–786. [CrossRef] [PubMed]
Pletnev, A.G.; Bray, M.; Lai, C.J. Chimeric tick-borne encephalitis and dengue type 4 viruses: Effects of
mutations on neurovirulence in mice. J. Virol. 1993, 67, 4956–4963. [PubMed]
Pryor, M.J.; Gualano, R.C.; Lin, B.; Davidson, A.D.; Wright, P.J. Growth restriction of dengue virus type 2
by site-specific mutagenesis of virus-encoded glycoproteins. J. Gen. Virol. 1998, 79, 2631–2639. [CrossRef]
[PubMed]
Muylaert, I.R.; Chambers, T.J.; Galler, R.; Rice, C.M. Mutagenesis of the N-linked glycosylation sites of the
yellow fever virus NS1 protein: Effects on virus replication and mouse neurovirulence. Virology 1996, 222,
159–168. [CrossRef]

Vaccines 2019, 7, 112

49.

50.

51.
52.

53.
54.
55.
56.
57.
58.

59.

60.

61.
62.

63.

64.

65.
66.

67.
68.

69.

20 of 21

Annamalai, A.S.; Pattnaik, A.; Sahoo, B.R.; Muthukrishnan, E.; Natarajan, S.K.; Steffen, D.; Vu, H.L.X.;
Delhon, G.; Osorio, F.A.; Petro, T.M.; et al. Zika Virus Encoding Non-Glycosylated Envelope Protein is
Attenuated and Defective in Neuroinvasion. J. Virol. 2017, 91, e01348-17. [CrossRef]
Pattnaik, A.; Palermo, N.; Sahoo, B.R.; Yuan, Z.; Hu, D.; Annamalai, A.S.; Vu, H.L.X.; Correas, I.; Prathipati, P.K.;
Destache, C.J.; et al. Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus
replication through in silico screening. Antivir. Res. 2018, 151, 78–86. [CrossRef]
Bullard, B.L.; Corder, B.N.; Gorman, M.J.; Diamond, M.S.; Weaver, E.A. Efficacy of a T Cell-Biased Adenovirus
Vector as a Zika Virus Vaccine. Sci. Rep. 2018, 8, 18017. [CrossRef]
Rossi, S.L.; Tesh, R.B.; Azar, S.R.; Muruato, A.E.; Hanley, K.A.; Auguste, A.J.; Langsjoen, R.M.; Paessler, S.;
Vasilakis, N.; Weaver, S.C. Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop.
Med. Hyg. 2016, 94, 1362–1369. [CrossRef]
Morrison, T.E.; Diamond, M.S. Animal Models of Zika Virus Infection, Pathogenesis, and Immunity. J. Virol.
2017, 91, e00009-17. [CrossRef]
Shan, C.; Xie, X.; Barrett, A.D.; Garcia-Blanco, M.A.; Tesh, R.B.; Vasconcelos, P.F.; Vasilakis, N.; Weaver, S.C.;
Shi, P.Y. Zika Virus: Diagnosis, Therapeutics, and Vaccine. ACS Infect. Dis. 2016, 2, 170–172. [CrossRef]
Khou, C.; Pardigon, N. Identifying Attenuating Mutations: Tools for a New Vaccine Design against
Flaviviruses. Intervirology 2017, 60, 8–18. [CrossRef]
Heinz, F.X.; Stiasny, K. Flaviviruses and flavivirus vaccines. Vaccine 2012, 30, 4301–4306. [CrossRef]
Barzon, L.; Palu, G. Current views on Zika virus vaccine development. Expert Opin. Biol. Ther. 2017, 17,
1185–1192. [CrossRef]
Larocca, R.A.; Abbink, P.; Peron, J.P.; Zanotto, P.M.; Iampietro, M.J.; Badamchi-Zadeh, A.; Boyd, M.;
Ng’ang’a, D.; Kirilova, M.; Nityanandam, R.; et al. Vaccine protection against Zika virus from Brazil. Nature
2016, 536, 474–478. [CrossRef]
Abbink, P.; Larocca, R.A.; De La Barrera, R.A.; Bricault, C.A.; Moseley, E.T.; Boyd, M.; Kirilova, M.; Li, Z.;
Ng’ang’a, D.; Nanayakkara, O.; et al. Protective efficacy of multiple vaccine platforms against Zika virus
challenge in rhesus monkeys. Science 2016, 353, 1129–1132. [CrossRef]
Dowd, K.A.; Ko, S.Y.; Morabito, K.M.; Yang, E.S.; Pelc, R.S.; DeMaso, C.R.; Castilho, L.R.; Abbink, P.; Boyd, M.;
Nityanandam, R.; et al. Rapid development of a DNA vaccine for Zika virus. Science 2016, 354, 237–240.
[CrossRef]
Chambers, T.J.; Nestorowicz, A.; Mason, P.W.; Rice, C.M. Yellow fever/Japanese encephalitis chimeric viruses:
Construction and biological properties. J. Virol. 1999, 73, 3095–3101.
Arroyo, J.; Miller, C.; Catalan, J.; Myers, G.A.; Ratterree, M.S.; Trent, D.W.; Monath, T.P. ChimeriVax-West
Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy. J. Virol.
2004, 78, 12497–12507. [CrossRef]
Richner, J.M.; Jagger, B.W.; Shan, C.; Fontes, C.R.; Dowd, K.A.; Cao, B.; Himansu, S.; Caine, E.A.; Nunes, B.T.D.;
Medeiros, D.B.A.; et al. Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. Cell
2017, 170, 273–283. [CrossRef]
Fontes-Garfias, C.R.; Shan, C.; Luo, H.; Muruato, A.E.; Medeiros, D.B.A.; Mays, E.; Xie, X.; Zou, J.;
Roundy, C.M.; Wakamiya, M.; et al. Functional Analysis of Glycosylation of Zika Virus Envelope Protein.
Cell Rep. 2017, 21, 1180–1190. [CrossRef]
Carbaugh, D.L.; Baric, R.S.; Lazear, H.M. Envelope Protein Glycosylation Mediates Zika Virus Pathogenesis.
J. Virol. 2019, 93, e00113-19. [CrossRef]
Duggal, N.K.; McDonald, E.M.; Weger-Lucarelli, J.; Hawks, S.A.; Ritter, J.M.; Romo, H.; Ebel, G.D.; Brault, A.C.
Mutations present in a low-passage Zika virus isolate result in attenuated pathogenesis in mice. Virology
2019, 530, 19–26. [CrossRef]
Hilgenfeld, R. Zika virus NS1, a pathogenicity factor with many faces. EMBO J. 2016, 35, 2631–2633.
[CrossRef]
Chen, H.W.; Huang, H.W.; Hu, H.M.; Chung, H.H.; Wu, S.H.; Chong, P.; Tao, M.H.; Pan, C.H. A poorly
neutralizing IgG2a/c response elicited by a DNA vaccine protects mice against Japanese encephalitis virus.
J. Gen. Virol. 2014, 95, 1983–1990. [CrossRef]
Brault, A.C.; Domi, A.; McDonald, E.M.; Talmi-Frank, D.; McCurley, N.; Basu, R.; Robinson, H.L.;
Hellerstein, M.; Duggal, N.K.; Bowen, R.A.; et al. A Zika Vaccine Targeting NS1 Protein Protects
Immunocompetent Adult Mice in a Lethal Challenge Model. Sci. Rep. 2017, 7, 14769. [CrossRef]

Vaccines 2019, 7, 112

70.

71.
72.

73.
74.
75.

21 of 21

Diamond, M.S.; Shrestha, B.; Marri, A.; Mahan, D.; Engle, M. B cells and antibody play critical roles in the
immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 2003, 77, 2578–2586.
[CrossRef]
Shrestha, B.; Diamond, M.S. Role of CD8+ T cells in control of West Nile virus infection. J. Virol. 2004, 78,
8312–8321. [CrossRef]
Scott, J.M.; Lebratti, T.J.; Richner, J.M.; Jiang, X.; Fernandez, E.; Zhao, H.; Fremont, D.H.; Diamond, M.S.;
Shin, H. Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice. J. Virol. 2018,
92, e00038-18. [CrossRef]
Barrett, P.N.; Mundt, W.; Kistner, O.; Howard, M.K. Vero cell platform in vaccine production: Moving
towards cell culture-based viral vaccines. Expert Rev. Vaccines 2009, 8, 607–618. [CrossRef]
Genzel, Y. Designing cell lines for viral vaccine production: Where do we stand? Biotechnol. J. 2015, 10,
728–740. [CrossRef]
Shan, C.; Muruato, A.E.; Nunes, B.T.D.; Luo, H.; Xie, X.; Medeiros, D.B.A.; Wakamiya, M.; Tesh, R.B.;
Barrett, A.D.; Wang, T.; et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in
mouse models. Nat. Med. 2017, 23, 763–767. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

